-+ 0.00%
-+ 0.00%
-+ 0.00%

Medicus Pharma Nine-Month Net Loss Widens 32% to USD 35.9 Million

PUBT·11/09/2026 12:31:44
Listen to the news
Medicus Pharma Nine-Month Net Loss Widens 32% to USD 35.9 Million
  • Medicus Pharma's Q3 2026 net loss narrowed 5% year-over-year to USD 15.2 million; operating expenses fell 6% to USD 14.5 million.
  • Operating expenses for the nine months ended September 30, 2026, rose 30% year-over-year to USD 34.5 million.
  • Management plans to prioritize incremental investment in CD228V and anticipates a substantial reduction in operating expenses in coming quarters.
  • The proposed SkinJect SPAC transaction contemplates a USD 135 million pre-money enterprise valuation, with completion anticipated in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611090730ACCESSWRNAPR_____1248714) on November 09, 2026, and is solely responsible for the information contained therein.